Protalix BioTherapeutics Sees Major Stake Increase Amid Goldman Sachs Expansion

Protalix BioTherapeutics, Inc. (PLX) has gained investor confidence with Goldman Sachs increasing its stake by 482.3% in Q1. The biopharmaceutical company develops recombinant therapeutic proteins through its ProCellEx platform and is expanding into drug delivery optimization. Protalix BioTherapeutics, Inc. offers Elelyso, Elfabrio, PRX-115, and PRX-119. With a commitment to developing innovative plant-based biologics, the company has the potential to lead the future of biologics production.

Protalix BioTherapeutics, Inc. (PLX) has seen a significant increase in investor confidence, with Goldman Sachs boosting its stake by 482.3% in the first quarter of 2025. This substantial investment underscores the market's growing interest in the company's innovative approach to developing recombinant therapeutic proteins through its ProCellEx platform. Additionally, Protalix BioTherapeutics is expanding its focus into drug delivery optimization, positioning itself at the forefront of plant-based biologics production.

The company's product portfolio includes Elelyso, Elfabrio, PRX-115, and PRX-119, each designed to address various rare genetic and metabolic disorders. Protalix's commitment to innovation and the potential of its proprietary platform have attracted significant attention from investors, leading to this substantial stake increase by Goldman Sachs.

The enzyme replacement therapy market, as reported by Towards Healthcare, is projected to grow significantly, reaching USD 24.71 billion by 2034, with a CAGR of 9.04% Enzyme Replacement Therapy Market Size Projects USD 24.71 Bn by 2034^[1]. This growth is driven by factors such as the increasing prevalence of rare genetic and metabolic disorders, advances in biotechnology, and improved regulatory support. Protalix's strategic position within this growing market further supports its potential for future success.